Neuromodulation of Inflammation and Endothelial Function

Launched by UNIVERSITY OF OKLAHOMA · Feb 4, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment method called low-level transcutaneous electrical stimulation (LLTS) of the vagus nerve to help patients with heart failure, specifically those with reduced heart function (known as heart failure with reduced ejection fraction, or HFrEF). The goal is to see if this treatment can improve symptoms, increase exercise ability, and enhance the quality of life for patients over a period of three months. By stimulating the vagus nerve, researchers hope to reduce inflammation and improve the function of blood vessels, which are often issues for people with heart failure.

To be eligible for this study, participants should be between the ages of 65 and 74 and have heart failure with a specific heart function measurement of 50% or less. However, individuals with certain conditions, such as recent severe heart problems, active cancer, or specific heart rhythm issues, cannot participate. Those who join the trial will receive LLTS for one hour a day over three months and will be monitored to see how this treatment affects their heart health and overall well-being. This research is important because it may lead to new, effective treatments for heart failure patients, especially as current options are sometimes limited.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Systolic heart failure with EF \< or equal to 50%.
• Exclusion Criteria:
• • 1. patients in overt congestive heart failure / recent acute myocardial infarction (\< 4 weeks) or Unstable angina
• • 2. Active malignancy
• • 3. unilateral or bilateral vagotomy
• • 4. pregnant patients
• • 5. End stage liver disease
• • 6. history of recurrent vasovagal syncope, Sick sinus syndrome with no pacemaker, 2nd or 3rd degree AV block.
• • 7. Significant hypotension (Blood pressure \< 90 mm Hg) secondary to autonomic dysfunction